Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10%

Published:December 02, 2016DOI:


      To determine the added value of prostate magnetic resonance imaging (MRI) to the Prostate Cancer Prevention Trial risk calculator.


      Between January 2012 and December 2015, 339 patients underwent prostate MRI prior to biopsy at our institution. MRI was considered positive if there was at least 1 Prostate Imaging Reporting and Data System 4 or 5 MRI suspicious region. Logistic regression was used to develop 2 models: biopsy outcome as a function of the (1) Prostate Cancer Prevention Trial risk calculator alone and (2) combined with MRI findings.


      When including all patients, the Prostate Cancer Prevention Trial with and without MRI models performed similarly (area under the curve [AUC] = 0.74 and 0.78, P = .06). When restricting the cohort to patients with estimated risk of high-grade (Gleason ≥7) prostate cancer ≤10%, the model with MRI outperformed the Prostate Cancer Prevention Trial alone model (AUC = 0.69 and 0.60, P = .01). Within this cohort of patients, there was no significant difference in discrimination between models for those with previous negative biopsy (AUC = 0.61 vs 0.63, P = .76), whereas there was a significant improvement in discrimination with the MRI model for biopsy-naïve patients (AUC = 0.72 vs 0.60, P = .01).


      The use of prostate MRI in addition to the Prostate Cancer Prevention Trial risk calculator provides a significant improvement in clinical risk discrimination for patients with estimated risk of high-grade (Gleason ≥7) prostate cancer ≤10%. Prebiopsy prostate MRI should be strongly considered for these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Futterer J.J.
        • Briganti A.
        • De Visschere P.
        • et al.
        Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature.
        Eur Urol. 2015; 68: 1045-1053
        • Schoots I.G.
        • Roobol M.J.
        • Nieboer D.
        • et al.
        Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
        Eur Urol. 2015; 68: 438-450
        • Valerio M.
        • Donaldson I.
        • Emberton M.
        • et al.
        Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review.
        Eur Urol. 2015; 68: 8-19
        • Siddiqui M.M.
        • Rais-Bahrami S.
        • Turkbey B.
        • et al.
        Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
        JAMA. 2015; 313: 390-397
        • Mowatt G.
        • Scotland G.
        • Boachie C.
        • et al.
        The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localization of prostate abnormalities for biopsy: a systematic review and economic evaluation.
        Health Technol Assess. 2013; 17: 1-281
        • Kim E.H.
        • Andriole G.L.
        Prostate-specific antigen-based screening: controversy and guidelines.
        BMC Med. 2015; 13: 1
        • Louie K.S.
        • Seigneurin A.
        • Cathcart P.
        • Sasieni P.
        Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
        Ann Oncol. 2015; 26: 848-864
        • Ankerst D.P.
        • Hoefler J.
        • Bock S.
        • et al.
        Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
        Urology. 2014; 83: 1362-1368
        • Rais-Bahrami S.
        • Siddiqui M.M.
        • Vourganti S.
        • et al.
        Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
        BJU Int. 2015; 115: 381-388
        • Salami S.S.
        • Vira M.A.
        • Turkbey B.
        • et al.
        Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
        Cancer. 2014; 120: 2876-2882
        • Shakir N.A.
        • George A.K.
        • Siddiqui M.M.
        • et al.
        Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
        J Urol. 2014; 192: 1642-1649
        • Barentsz J.O.
        • Richenberg J.
        • Clements R.
        • et al.
        ESUR prostate MR guidelines.
        Eur Radiol. 2012; 22: 746-757
        • Weinreb J.C.
        • Barentsz J.O.
        • Choyke P.L.
        • et al.
        PIRADS Version 2.
        (Available at:) (Accessed July 9)
        • Polanec S.
        • Helbich T.H.
        • Bickel H.
        • et al.
        Head-to-head comparison if PI-RADS v2 and PI-RADS v1.
        Eur J Radiol. 2016; 85: 1125-1131
        • Park Y.S.
        • Jung D.C.
        • Oh T.Y.
        • et al.
        Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers.
        Radiology. 2016; 280: 108-116
        • Weaver J.K.
        • Kim E.H.
        • Vetter J.M.
        • et al.
        Presence of magnetic resonance imaging suspicious lesion predicts Gleason 7 or greater prostate cancer in biopsy-naïve patients.
        Urology. 2016; 88: 119-124
        • Kim E.H.
        • Vemana G.
        • Johnson M.H.
        • et al.
        Magnetic resonance imaging-targeted vs. conventional transrectal ultrasound-guided prostate biopsy: single-institution, matched cohort comparison.
        Urol Oncol. 2015; 33 (e1-109.e6): 109
        • Epstein J.I.
        • Lars E.
        • Mahul A.
        • et al.
        The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.
        Am J Surg Pathol. 2016; 40: 244-252
        • Thompson J.E.
        • Moses D.
        • Shnier R.
        • et al.
        Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
        J Urol. 2014; 192: 67-74
        • Itatni R.
        • Namimoto T.
        • Atsuji S.
        • et al.
        Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies.
        Eur J Radiol. 2014; 83: 1740-1745
        • Tonttila P.P.
        • Lantto J.
        • Paakko E.
        • et al.
        Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naïve men with suspected prostate cancer based on elevated prostate-specific antigen values: results from a randomized prospective blinded controlled trial.
        Eur Urol. 2016; 69: 419-425
        • Wysock J.S.
        • Rosenkrantz A.B.
        • Huang W.C.
        • et al.
        A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.
        Eur Urol. 2014; 66: 343-351
        • Puech P.
        • Rouviere O.
        • Renard-Penna R.
        • et al.
        Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy-prospective multicenter study.
        Radiology. 2013; 268: 461-469